Table 1.
Clinical characteristics
| Items | Apatinib (N=10) | Apatinib plus cTACE (N=12) | Apatinib plus DEB-TACE (N=13) | P value |
|---|---|---|---|---|
| Age (years), mean ± SD | 58.7±7.8 | 56.9±9.7 | 55.9±14.3 | 0.833 |
| ≤60 years, No. (%) | 6 (60.0) | 7 (58.3) | 7 (53.8) | 0.952 |
| >60 years, No. (%) | 4 (40.0) | 5 (41.7) | 6 (46.2) | |
| Gender, No. (%) | 0.168 | |||
| Female | 2 (20.0) | 3 (25.0) | 7 (53.8) | |
| Male | 8 (80.0) | 9 (75.0) | 6 (46.2) | |
| Weight, No. (%) | 0.976 | |||
| ≤60 kg | 5 (50.0) | 6 (50.0) | 7 (53.8) | |
| >60 kg | 5 (50.0) | 6 (50.0) | 6 (46.2) | |
| HBV status, No. (%) | 0.186 | |||
| Negative | 8 (80.0) | 5 (41.7) | 7 (53.8) | |
| Positive | 2 (20.0) | 7 (58.3) | 6 (46.2) | |
| ECOG score, No. (%) | 0.944 | |||
| 1 | 7 (70.0) | 9 (75.0) | 9 (69.2) | |
| 2 | 3 (30.0) | 3 (25.0) | 4 (30.8) | |
| Child-Pugh stage, No. (%) | 0.984 | |||
| A | 3 (30.0) | 4 (33.3) | 4 (30.8) | |
| B | 7 (70.0) | 8 (66.7) | 9 (69.2) | |
| Number of intrahepatic tumors, No. (%) | 0.154 | |||
| ≤3 | 4 (40.0) | 2 (16.7) | 7 (53.8) | |
| >3 | 6 (60.0) | 10 (83.3) | 6 (46.2) | |
| Macroscopic vascular invasion, No. (%) | 0.602 | |||
| No | 7 (70.0) | 7 (58.3) | 10 (76.9) | |
| Yes | 3 (30.0) | 5 (41.7) | 3 (23.1) | |
| Tumor size (cm), mean ± SD | 6.8±4.4 | 6.8±4.6 | 7.9±2.7 | 0.724 |
| ≤5.0 cm, No. (%) | 3 (30.0) | 5 (41.7) | 1 (7.7) | 0.142 |
| >5.0 cm, No. (%) | 7 (70.0) | 7 (58.3) | 12 (92.3) | |
| Lymph node metastasis, No. (%) | 0.152 | |||
| No | 0 (0.0) | 2 (16.7) | 4 (30.8) | |
| Yes | 10 (100.0) | 10 (83.3) | 9 (69.2) | |
| Distant metastasis, No. (%) | 0.764 | |||
| No | 3 (30.0) | 3 (25.0) | 5 (38.5) | |
| Yes | 7 (70.0) | 9 (75.0) | 8 (61.5) | |
| TNM stage, No. (%) | 0.689 | |||
| III | 3 (30.0) | 4 (33.3) | 6 (46.2) | |
| IV | 7 (70.0) | 8 (66.7) | 7 (53.8) | |
| CA199￡, No. (%) | 0.808 | |||
| Normal | 4 (40.0) | 4 (33.3) | 6 (46.2) | |
| Abnormal | 6 (60.0) | 8 (66.7) | 7 (53.8) | |
| Bile duct dilatation, No. (%) | 0.952 | |||
| No | 6 (60.0) | 7 (58.3) | 7 (53.8) | |
| Yes | 4 (40.0) | 5 (41.7) | 6 (46.2) | |
| Biliary drainage, No. (%) | 0.962 | |||
| No | 8 (80.0) | 9 (75.0) | 10 (76.9) | |
| Yes | 2 (20.0) | 3 (25.0) | 3 (23.1) | |
| Previous therapy, No. (%) | 0.877 | |||
| No | 6 (60.0) | 8 (66.7) | 10 (76.9) | |
| Chemotherapy | 1 (10.0) | 1 (8.3) | 0 (0.0) | |
| Radiotherapy | 1 (10.0) | 1 (8.3) | 2 (15.4) | |
| Surgery and chemoradiotherapy | 2 (20.0) | 2 (16.7) | 1 (7.7) |
Comparison was determined by one-way analysis of variance (ANOVA) or Chi-square test.
￡
normal: CA199 level ≤27.0 U/mL, abnormal: CA199 level >27.0 U/mL.
cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization. SD, standard deviation; HBV, hepatitis B virus; ECOG, Eastern Co-operative Oncology Group; CA199, carbohydrate antigen 199.